MRCT signs agreement to develop immunotherapy for respiratory disease
The UK-based Medical Research Council (MRC) and MRC Technology (MRCT) in the UK have signed exclusive agreements with Centocor in the US, now known as Centocor Ortho Biotech, for the development of a novel immunotherapy targeting respiratory disease.
The UK-based Medical Research Council (MRC) and MRC Technology (MRCT) in the UK have signed exclusive agreements with Centocor in the US, now known as Centocor Ortho Biotech, for the development of a novel immunotherapy targeting respiratory disease.
The potential therapy was identified at the MRC Laboratory of Molecular Biology as part of a basic research programme. This research was quickly identified as having therapeutic potential and MRCT's Drug Discovery Group performed further work in an example of translational research.
Centocor Ortho Biotech will make development payments on net sales that may result from the commercialisation of future products. The immunotherapy has not been disclosed at this stage.
